Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma.
Huang X, Liu Y, Wang Y, Bailey C, Zheng P, Liu Y.
Cancers (Basel). 2021 Feb 9;13(4):694. doi: 10.3390/cancers13040694.

Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.
Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y.
Nanomedicine. 2020 Jul 30:102278. doi: 10.1016/j.nano.2020.102278.

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y
Oncogene. 2020 Apr;39(14):3015-3027. doi: 10.1038/s41388-020-1201-z.

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.
Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P.
Cancers (Basel). 2020 Jan 24;12(2):284. doi: 10.3390/cancers12020284. 

Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
Liu Y, Zheng P.
Trends Pharmacol Sci. 2020 Jan;41(1):4-12. doi: 10.1016/j.tips.2019.11.003. 

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y.
Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1.

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Liu Y, Zheng P.
Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009. 

Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice.
Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P.
Cell Res. 2018 Apr;28(4):433-447. doi: 10.1038/s41422-018-0012-z.

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y. 
Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0.

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. 
Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, et al.
Blood. 2014;123(22):3512-23. doi: 10.1182/blood-2013-12-545335.

Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.
Chen GY, Brown NK, Zheng P, Liu Y.
Glycobiology. 2014 Sep;24(9):800-6. doi: 10.1093/glycob/cwu068.

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.
Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu Y.
Blood. 2014 Aug 14;124(7):1127-35. doi: 10.1182/blood-2013-12-544221. 

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.
Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, et al.
Nat Biotechnol. 2011 May;29(5):428-35. doi: 10.1038/nbt.1846.

Targeting HIF1α eliminates cancer stem cells in hematological malignancies.
Wang Y, Liu Y, Malek SN, Zheng P, Liu Y.
Cell Stem Cell. 2011 Apr 8;8(4):399-411. doi: 10.1016/j.stem.2011.02.006. 

Sialoside-based pattern recognitions discriminating infections from tissue injuries.
Liu Y, Chen GY, Zheng P.
Curr Opin Immunol. 2011 Feb;23(1):41-5. doi: 10.1016/j.coi.2010.10.004.

CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.
Chen GY, Tang J, Zheng P, Liu Y.
Science. 2009;323:1722-5. doi: 10.1126/science.1168988. 

A dinucleotide deletion in CD24 confers protection against autoimmune diseases.
Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH, Guinther N, et al.
PLoS Genet. 2007 Apr 6;3(4):e49. doi: 10.1371/journal.pgen.0030049. 

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Kocak E, Lute K, Chang X, May KF, Jr., Exten KR, Zhang H, et al.
Cancer Res. 2006;66(14):7276-84. doi: 10.1158/0008-5472.CAN-05-2128.

Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Lute KD, May KF, Lu P, Zhang H, Kocak E, Mosinger B, et al.
Blood. 2005. PubMed PMID: 16037385. doi: 10.1182/blood-2005-06-2298.

Anti-human CTLA-4 monoclonal antibody promotes T cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.
May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, et al.
Blood. 2005;105:1114-20. PubMed PMID: 15486062. doi: 10.1182/blood-2004-07-2561.

CD24 is a genetic modifier for risk and progression of multiple sclerosis.
Zhou Q, Rammohan K, Lin S, Robinson N, Li O, Liu X, Bai XF, Yin L, et al.
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15041-6. doi: 10.1073/pnas.2533866100.